Trials / Completed
CompletedNCT06600607
Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Pharmacodynamic Effects of Pregabalin in Healthy Male Adults
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Latigo Biotherapeutics · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled within-participant crossover study in healthy male participants 18-55 years of age to assess pain tolerance during a cold pressor test. The study will be conducted at a single center in New Zealand.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin 300 mg | pregabalin is an FDA-approved anticonvulsant medication commonly used to treat nerve pain |
| OTHER | Placebo | biologically inactive placebo comparator |
Timeline
- Start date
- 2024-10-07
- Primary completion
- 2024-10-27
- Completion
- 2024-10-27
- First posted
- 2024-09-19
- Last updated
- 2025-05-04
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06600607. Inclusion in this directory is not an endorsement.